Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.67 |
| ▸ | PLA2G2A | P14555 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2159717 | 0.92 | FAAH (0.74) | FAAHPLA2G2AALDH1A1TSHRPKM | |
| SCHEMBL10234769 | 0.90 | FAAH (0.74) | FAAHPLA2G2AALDH1A1TSHRPKM | |
| SCHEMBL2159739 | 0.90 | FAAH (0.79) | FAAHPLA2G2AALDH1A1TSHRPKM | |
| SCHEMBL2197934 | 0.89 | FAAH (0.81) | FAAHPLA2G2AALDH1A1TSHRPKM | |
| SCHEMBL2169399 | 0.89 | FAAH (0.75) | FAAHPLA2G2AALDH1A1TSHRPKM | |
| SCHEMBL4083757 | 0.88 | FAAH (0.73) | FAAHPLA2G2AALDH1A1TSHRPKM | |
| SCHEMBL2159916 | 0.87 | FAAH (0.87) | FAAHPLA2G2AALDH1A1TSHRPKM | |
| SCHEMBL9958778 | 0.87 | FAAH (0.67) | FAAHPLA2G2AALDH1A1TSHRPKM | |
| SCHEMBL2168787 | 0.87 | FAAH (0.74) | FAAHPLA2G2AALDH1A1TSHRPKM | |
| SCHEMBL9951898 | 0.86 | FAAH (0.65) | FAAHPLA2G2AALDH1A1TSHRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9657012-B2 | FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657012-B2 | FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657012-B2 | FAAH inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-2655356-B1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-08-03 | — | — | EP | disclosed |
| EP-2655356-B1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-20150175599-A1 | FAAH Inhibitors | IRONWOOD PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| WO-2014004676-A1 | USE OF FAAH INHIBITORS AS NEUROPROTECTIVE AGENTS IN THE CNS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-2655356-A1 | FAAH INHIBITORS | Ironwood Pharmaceuticals, Inc. (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012088469-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012088469-A1 | FAAH INHIBITORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150175599-A1 | FAAH Inhibitors | FAAH, FAAH2, ASAH1 | FAAH 1/4885PLA2G2A 63/4885ALDH1A1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.